CA2150554A1 - Composition pharmaceutique a base de cyclodextrine et de polymere - Google Patents

Composition pharmaceutique a base de cyclodextrine et de polymere

Info

Publication number
CA2150554A1
CA2150554A1 CA002150554A CA2150554A CA2150554A1 CA 2150554 A1 CA2150554 A1 CA 2150554A1 CA 002150554 A CA002150554 A CA 002150554A CA 2150554 A CA2150554 A CA 2150554A CA 2150554 A1 CA2150554 A1 CA 2150554A1
Authority
CA
Canada
Prior art keywords
alpha
beta
defined above
alkyl
cyclodextrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002150554A
Other languages
English (en)
Inventor
Sheng-Wan Tsao
Lyle M. Bowman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/984,445 external-priority patent/US5332582A/en
Application filed by Individual filed Critical Individual
Publication of CA2150554A1 publication Critical patent/CA2150554A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
CA002150554A 1992-12-02 1993-12-01 Composition pharmaceutique a base de cyclodextrine et de polymere Abandoned CA2150554A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US07/984,445 US5332582A (en) 1990-06-12 1992-12-02 Stabilization of aminosteroids for topical ophthalmic and other applications
US07/984,445 1992-12-02
US15516793A 1993-11-19 1993-11-19
US08/155,167 1993-11-19

Publications (1)

Publication Number Publication Date
CA2150554A1 true CA2150554A1 (fr) 1994-06-09

Family

ID=26852057

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002150554A Abandoned CA2150554A1 (fr) 1992-12-02 1993-12-01 Composition pharmaceutique a base de cyclodextrine et de polymere

Country Status (6)

Country Link
EP (1) EP0674528A4 (fr)
JP (1) JPH08503951A (fr)
CN (1) CN1103316A (fr)
AU (1) AU672862B2 (fr)
CA (1) CA2150554A1 (fr)
WO (1) WO1994012217A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW434023B (en) * 1995-09-18 2001-05-16 Novartis Ag Preserved ophthalmic composition
JP3940209B2 (ja) * 1996-11-14 2007-07-04 株式会社資生堂 可溶化化粧料
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6656456B2 (en) 1998-11-23 2003-12-02 The Procter & Gamble Company Skin deodorizing compositions
CN1328443A (zh) * 1998-11-23 2001-12-26 宝洁公司 皮肤除臭和卫生消毒组合物
JP2003529567A (ja) * 2000-03-10 2003-10-07 インサイト・ビジョン・インコーポレイテッド 後眼部眼疾患を治療および予防する方法と組成物
SI1278549T1 (sl) 2000-05-02 2009-04-30 Theravance Inc Sestavek, ki vsebuje ciklodekstrin in glikopeptidni antibiotik
WO2001083520A2 (fr) 2000-05-02 2001-11-08 Theravance,Inc Derives polyacides de glycopeptides
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
ES2302733T3 (es) 2000-06-22 2008-08-01 Theravance, Inc. Derivados carboxi-sacaridos de glucopeptido.
AU2001259816A1 (en) 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
JP4860895B2 (ja) * 2000-09-26 2012-01-25 日清ファルマ株式会社 リン酸プレドニゾロンナトリウム液体製剤
CA2445606A1 (fr) * 2001-05-11 2002-11-21 Pacific Pharmaceuticals Limited Composition pharmaceutique destinee a masquer le gout de certains medicaments
EP1621199B8 (fr) * 2003-04-18 2011-01-19 Advanced Medicine Research Institute Remedes a des affections, a usage ophtalmique
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
WO2006040839A1 (fr) * 2004-10-15 2006-04-20 Advanced Medicine Research Institute Gouttes oculaires et trousses de traitement de maladies oculaires
JP2007177149A (ja) * 2005-12-28 2007-07-12 Shield Lab:Kk チオクト酸又はジヒドロリポ酸と分岐鎖シクロデキストリンとの包接化合物
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US20100311738A1 (en) * 2007-12-21 2010-12-09 Aop Orphan Pharmaceuticals Ag Pharmaceutical Composition For The Parenteral Administration Of Ultrashort-Effective Beta-Adrenoreceptor Antagonists
US10980818B2 (en) 2009-03-06 2021-04-20 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
US10201548B2 (en) * 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
CN103327939B (zh) 2010-10-15 2017-05-24 科尼尔赛德生物医学公司 用于进入眼睛的装置
KR20150083117A (ko) 2012-11-08 2015-07-16 클리어사이드 바이오메디컬, 인코포레이드 인간 대상체에서 안구 질병을 치료하기 위한 방법 및 장치
WO2014127020A1 (fr) * 2013-02-12 2014-08-21 Ys Pharmtech Formulations d'épinéphrine pour produits médicinaux
CN110302004B (zh) 2013-05-03 2023-04-28 科尼尔赛德生物医学公司 用于眼部注射的设备和方法
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
CN103990137A (zh) * 2014-04-30 2014-08-20 福建融和药业有限公司 一种粘膜粘附性聚合物眼用药物的缓释剂
EP3413851B1 (fr) 2016-02-10 2023-09-27 Clearside Biomedical, Inc. Emballage
CA3062845A1 (fr) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systemes et methodes pour l'administration de medicaments par voie ophtalmique
US10973681B2 (en) 2016-08-12 2021-04-13 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
CN109136177B (zh) * 2018-08-03 2021-09-17 湖南大学 一种地塞米松缓释体系以及一种成骨分化诱导液和应用
RU2740287C1 (ru) * 2019-08-30 2021-01-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) 3д-матриксная структура для доставки лекарственных препаратов
CN115380899A (zh) * 2022-08-30 2022-11-25 陕西科技大学 一种凝胶型腐植酸缓释农药及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
NZ225045A (en) * 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
IE63392B1 (en) * 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
ATE100712T1 (de) * 1989-05-24 1994-02-15 Innovet Inc Hypoallergene anaesthesierende/hypnotische steroide arzneizubereitung.
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins

Also Published As

Publication number Publication date
JPH08503951A (ja) 1996-04-30
AU672862B2 (en) 1996-10-17
EP0674528A1 (fr) 1995-10-04
WO1994012217A1 (fr) 1994-06-09
AU5684194A (en) 1994-06-22
EP0674528A4 (fr) 1996-06-26
CN1103316A (zh) 1995-06-07

Similar Documents

Publication Publication Date Title
CA2150554A1 (fr) Composition pharmaceutique a base de cyclodextrine et de polymere
US5538721A (en) Stabilization of aminosteroids for topical ophthalmic and other applications
Loftsson et al. Cyclodextrins and topical drug delivery to the anterior and posterior segments of the eye
Loftssona et al. Cyclodextrins in ophthalmic drug delivery
EP0794783B1 (fr) Cyclodextrines utilisees comme agents de suspension dans des suspensions pharmaceutiques
US8633172B2 (en) Cyclodextrin nanotechnology for ophthalmic drug delivery
Loftsson et al. Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye
EP0730443B1 (fr) Suspension d'etabonate de loteprednol
US20040152664A1 (en) Prednisolone compositions
JPH06239748A (ja) セチリジン含有抗アレルギー点眼点鼻用組成物
US4642305A (en) Eye drops composition
CN102724965B (zh) 含羧乙烯基聚合物的纳米颗粒混悬液
EP1567125A2 (fr) Compositions pharmaceutiques adaptees au traitement de maladies ophtalmiques
US20050059615A1 (en) Transmucosal dosage forms for brain-targeted steroid chemical delivery systems
US5977180A (en) Anandamide analog compositions and method of treating intraocular hypertension using same
WO2007013590A1 (fr) Système non invasif d'administration de médicament qui vise le tissu postérieur de l'œil au moyen d’une composition solide
Patil et al. Advances in progesterone delivery systems: Still work in progress?
JP5087242B2 (ja) ゲル状組成物を用いた後眼部組織への非侵襲性ドラッグデリバリーシステム
JP3147076B2 (ja) ロテプレドノール エタボネート水性懸濁液
CN115837027A (zh) 一种眼用地塞米松药物组合物
TW201932110A (zh) 供每日一次用之苯並咪唑化合物的眼用組成物
Bary Considerations in the use of cyclodextrins in the reformation of ophthalmic suspensions as solutions

Legal Events

Date Code Title Description
FZDE Discontinued